Pfizer Inc. [NYSE: PFE] closed the trading session at $36.04 on 11/17/20. The day’s price range saw the stock hit a low of $35.82, while the highest price level was $36.50. The company report on November 17, 2020 that Scott+Scott Attorneys at Law LLP Investigates Pfizer, Inc.’s (PFE) Directors and Officers for Breach of Fiduciary Duties.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Pfizer, Inc. (“Pfizer” or “Company”) (NYSE: PFE) breached their fiduciary duties to PFE and its shareholders. If you are a Pfizer shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or firstname.lastname@example.org.
Scott+Scott is investigating whether Pfizer’s board of directors or senior management failed to manage Pfizer in an acceptable manner, in breach of their fiduciary duties to Pfizer, and whether Pfizer has suffered damages as a result.
The stocks have a year to date performance of -8.01 percent and weekly performance of -6.83 percent. The stock has been moved at -4.23 percent over the last six months. The stock has performed -4.66 percent around the most recent 30 days and changed -5.80 percent over the most recent 3-months.
If compared to the average trading volume of 29.06M shares, PFE reached to a volume of 46573137 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $41.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 10, 2020. While these analysts kept the previous recommendation, Atlantic Equities dropped their target price from $44 to $39. The new note on the price target was released on October 12, 2020, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise to $38, while Berenberg analysts kept a Hold rating on PFE stock.
The Average True Range (ATR) for Pfizer Inc. is set at 1.38, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 4.00. The Price to Book ratio for the last quarter was 3.07, with the Price to Cash per share for the same quarter was set at 1.94. Price to Free Cash Flow for PFE in the course of the last twelve months was 93.19 with Quick ratio for the last quarter at 1.10.
PFE stock trade performance evaluation
Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.83. With this latest performance, PFE shares dropped by -4.66% in over the last four-week period, additionally sinking by -4.23% over the last 6 months – not to mention a drop of -3.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 44.59, with the RSI for the last a single of trading hit 41.09, and the three-weeks RSI is set at 45.83 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 36.81, while it was recorded at 37.61 for the last single week of trading, and 36.03 for the last 200 days.
Pfizer Inc. [PFE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +27.28 and a Gross Margin at +71.52. Pfizer Inc.’s Net Margin is presently recorded at +31.44.
Return on Total Capital for PFE is now 12.69, given the latest momentum, and Return on Invested Capital for the company is 16.56. Return on Equity for this stock inclined to 25.71, with Return on Assets sitting at 9.95. When it comes to the capital structure of this company, Pfizer Inc. [PFE] has a Total Debt to Total Equity ratio set at 84.69. Additionally, PFE Total Debt to Total Capital is recorded at 45.85, with Total Debt to Total Assets ending up at 31.93. Long-Term Debt to Equity for the company is recorded at 58.62, with the Long-Term Debt to Total Capital now at 31.73.
Reflecting on the efficiency of the workforce at the company, Pfizer Inc. [PFE] managed to generate an average of $184,247 per employee. Receivables Turnover for the company is 6.18 with a Total Asset Turnover recorded at a value of 0.32.Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.
Earnings per share (EPS) analysis for Pfizer Inc. [PFE] stock
With the latest financial reports released by the company, Pfizer Inc. posted 0.55/share EPS, while the average EPS was predicted by analysts to be reported at 0.57/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -3.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 3.70%.
Pfizer Inc. [PFE]: Insider Ownership positions
There are presently around $137,827 million, or 71.50% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 451,075,687, which is approximately -1.273% of the company’s market cap and around 0.05% of the total institutional ownership; BLACKROCK INC., holding 414,768,435 shares of the stock with an approximate value of $14.95 billion in PFE stocks shares; and STATE STREET CORP, currently with $10.42 billion in PFE stock with ownership of nearly -3.282% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,317 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 102,399,567 shares. Additionally, 1,050 investors decreased positions by around 214,867,556 shares, while 231 investors held positions by with 3,507,021,139 shares. The mentioned changes placed institutional holdings at 3,824,288,262 shares, according to the latest SEC report filing. PFE stock had 167 new institutional investments in for a total of 12,737,785 shares, while 92 institutional investors sold positions of 12,260,205 shares during the same period.